S&P 500 Gains and Losses Today: Pepsi Stock Turns Higher; Elevance Health Tumbles

U.S. equities closed higher on Thursday, July 17, 2025, with the S&P 500 and Nasdaq reaching record highs, fueled by better-than-expected June retail sales signaling resilient consumer spending. PepsiCo surged 7.5% on strong quarterly results and an improved profit outlook, while Albemarle gained 7.6% due to rising lithium prices. Conversely, Elevance Health shares plunged 12.2% after cutting full-year guidance citing ACA and Medicaid cost pressures, dragging down other health insurers, and Abbott Laboratories fell 8.5% despite a Q2 beat, due to a narrowed full-year outlook.

Analysis

U.S. equity markets reached new highs, with the S&P 500 advancing 0.5% and the Nasdaq 0.7%, driven by stronger-than-expected June retail sales that suggest continued consumer resilience. However, this broad market strength masks significant sector-specific divergence and a clear focus on corporate guidance. Consumer-facing companies demonstrated notable strength; PepsiCo (PEP) gained 7.5% after exceeding quarterly estimates and raising its profit outlook, aided by a weaker dollar, while Snap-On (SNA) surged 7.9% on resilient gross margins and renewed growth in its U.S. tools segment. In commodities, a supply-side catalyst emerged as Albemarle (ALB) jumped 7.6% after a Chinese competitor halted production, potentially signaling a floor for lithium prices after a prolonged slump. Conversely, the healthcare sector faced intense pressure. Elevance Health (ELV) plummeted 12.2% after slashing its full-year forecast due to rising ACA and Medicaid costs, a systemic issue that also dragged down peers Molina (MOH) and Centene (CNC). Similarly, Abbott Laboratories (ABT) fell 8.5% as a narrowed full-year outlook, driven by declining COVID-19 test sales, overshadowed an otherwise solid quarterly earnings beat. The market also penalized M&A-related costs, with both Omnicom (OMC) and Interpublic Group (IPG) falling over 4% after Omnicom reported lower profits tied to its ongoing acquisition.

Key Decisions for Investors

• Given the bifurcation between strong consumer names and pressured healthcare stocks, investors should scrutinize forward guidance over backward-looking earnings, as seen in the divergent reactions to PepsiCo and Abbott Labs.
• The sharp sell-off in the managed care sector, led by Elevance Health's guidance cut, signals systemic cost pressures, warranting a cautious stance or potential underweighting of health insurers like ELV, MOH, and CNC.
• The supply disruption in China presents a tactical catalyst for the lithium sector; investors could consider initiating or adding to positions in producers like Albemarle (ALB) on the potential for a recovery in the commodity's price.
• The negative reaction to Omnicom and Interpublic highlights market sensitivity to M&A integration costs, suggesting that investors should closely monitor synergy and margin developments for companies involved in large-scale acquisitions.